Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291134 · ClinicalTrials.gov registry record
PureGen: Radiographic Analysis of Fusion for ACDF
A clinical trial, sponsored by Alphatec Spine.
- Terminated
- Registry status
- 30
- Enrollment target
NCT01291134 is a clinical trial that was terminated before completion, run by Alphatec Spine. The registered enrollment target is 30 participants.
The verdict
NCT01291134 was terminated before completion, sponsored by Alphatec Spine.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).
Interventions
- BIOLOGICAL PureGen Osteoprogenitor Cell Allograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291134
The ClinicalTrials.gov registry entry for NCT01291134 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alphatec Spine, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PureGen Osteoprogenitor Cell Allograft is the first listed.
NCT01291134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01291134 about?
NCT01291134 is a clinical study titled "PureGen: Radiographic Analysis of Fusion for ACDF". The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).
What is the current status of trial NCT01291134?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2011-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01291134?
The interventions under investigation include: PureGen Osteoprogenitor Cell Allograft (BIOLOGICAL).
Who is sponsoring clinical trial NCT01291134?
This trial is sponsored by Alphatec Spine, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.